实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (5): 583-586.doi: 10.3969/j.issn.1672-5069.2016.05.018

• 肝硬化 • 上一篇    下一篇

脑活素联合微生态制剂治疗肝性脑病患者疗效观察*

陈振道, 陈浩   

  1. 525100 广东省化州市人民医院消化内科(陈振道); 广东省人民医院消化内科(陈浩)
  • 收稿日期:2016-01-04 出版日期:2016-09-10 发布日期:2016-10-12
  • 作者简介:陈振道,男,33岁,大学本科,主治医师。E-mail:czd0813@sina.com
  • 基金资助:
    国家自然科学基金资助项目(编号:81300279); 中国博士后科学基金资助项目(编号:2012M521579); 广东省自然科学基金资助项目(编号:S2013040013549); 广东省医学科研基金资助项目(编号:A2014020)

Observation of the clinical efficacy of cerebrolysin combined with probiotics in treatment of patients with hepatic encephalopathy

Chen Zhendao, Chen Hao.   

  1. Department of Gastroenterology,People's Hospital,Huazhou 525100,Guangdong Province,People’s Republic of China. E-mail:czd0813@sina.com
  • Received:2016-01-04 Online:2016-09-10 Published:2016-10-12

摘要: 目的观察脑活素和微生态制剂联合治疗肝性脑病患者的临床疗效。方法选取2014年3月至2015年4月广东省化州市人民医院收治的76例肝性脑病患者,采用随机数字表法分为对照组和联合用药组,每组38例。给予对照组双歧杆菌乳杆菌三联活菌片,联合用药组则在给予微生态制剂的同时,给予脑活素静脉滴注。两组均观察28 d。采用干片法检测血氨水平,采用ELISA双抗体夹心法检测肿瘤坏死因子-α( TNF-α)水平;采用数字连接试验(NCT)和数字符号试验(DST)检测受试者智力能力。结果经过4周治疗后,对照组患者NCT和DST评分为(70.47±8.15)和(31.52±8.32),而联合用药组则分别为(41.06±6.61)和(56.89±9.23),联合用药组明显优于对照组,差异具有统计学意义(P<0.05);对照组血氨、ALT、TNF-α、TBIL分别为(69.71±19.56)μmol/L、(66.34±15.82) U/L、(346.75±45.63) pg/ml和(51.32±8.77)μmol/L,而联合用药组则分别为(49.65±18.33)μmol/L、(58.48±12.66) U/L、(142.57±39.51) pg/ml和(40.19±8.24)μmol/L,联合用药组改善更明显,差异具有统计学意义(P<0.05)。结论脑活素联合微生态制剂治疗肝性脑病患者效果更为显著,值得临床进一步验证。

关键词: 肝性脑病, 脑活素, 微生态制剂, 治疗

Abstract: Objective To observe the clinical efficacy of combined treatment of cerebrolysin and probiotics for patients with hepatic encephalopathy(HE). Methods 76 patients with HE were randomly divided into combined treatment group and control group,with 38 cases in each. The patients in control group were treated with probiotics for 4 weeks,and the patients in combined treatment group were treated with cerebrolysin and probiotics for 4 weeks. The scores of number connection test (NCT) and digit symbol test (DST) were applied to evaluate brain functions.The blood ammonia,ALT,tumor necrosis factor-α (TNF-α) and serum bilirubin levels were assessed before and after the treatment. Results At the end of 4 week treatment,the scores of NCT and DST in control group were (70.47±8.15) and (31.52±8.32),while they were (41.06±6.61) and (56.89±9.23) respectively in combined treatment group,significantly different in the two groups(P<0.05);The levels of blood ammonia,ALT,TNF-α and TBIL in control group were(69.71±19.56) μmol/L,(66.34±15.82) U/L,(346.75±45.63) pg/ml,and(51.32±8.77) μmol/L,while they were(49.65±18.33) μmol/L,(58.48±12.66) U/L,(142.57±39.51) pg/ml and(40.19±8.24) μmol/L in combined treatment group,with statistically significant difference(P<0.05). Conclusion The clinical efficacy of cerebrolysin combined with probiotics for treatment of patients with HE is good,and it is worth to prove in clinical practice.

Key words: Hepatic encephalopathy, Cerebrolysin, Probiotics, Efficacy